An Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Backbone Regimens in Patients with Multiple Myeloma

被引：5
|
作者：
Moreau, Philippe [1 ]
Mateos, Maria-Victoria [2 ]
Blade, Joan [3 ]
Benboubker, Lotfi [4 ]
de la Rubia, Javier [5 ,6 ]
Facon, Thierry [7 ]
Comenzo, Raymond L. [8 ]
Fay, Joseph W. [9 ]
Qin, Xiang [10 ]
Masterson, Tara [10 ]
Schecter, Jordan [11 ]
Ahmadi, Tahamtan [10 ]
San Miguel, Jesus [12 ]
机构：
[1] Univ Hosp Nantes, Nantes, France
[2] Univ Hosp Salamanca IBSAL, Salamanca, Spain
[3] Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain
[4] Hop Bretonneau, CHU Tours, Tours, France
[5] Hosp La Fe, E-46009 Valencia, Spain
[6] Univ Catolica San Vicente Martir, Valencia, Spain
[7] CHRU Lille, F-59037 Lille, France
[8] Tufts Med Ctr, Boston, MA USA
[9] Baylor Inst Immunol Res, Dallas, TX USA
[10] Janssen Pharmaceut Res & Dev, Spring House, PA USA
[11] Janssen Pharmaceut Res & Dev, Raritan, NJ USA
[12] Univ Navarra Clin, Pamplona, Spain
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
10.1182/blood.V124.21.3359.3359
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Daratumumab (DARA) in Combination with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) in Patients with Newly Diagnosed Multiple Myeloma (MMY1001): Updated Results from an Open-Label, Phase 1b Study
    Chari, Ajai
    Usmani, Saad Z.
    Krishnan, Amrita
    Lonial, Sagar
    Comenzo, Raymond
    Wu, Kaida
    Wang, Jianping
    Doshi, Parul
    Weiss, Brendan M.
    Schecter, Jordan
    Jakubowiak, Andrzej J.
    [J]. BLOOD, 2017, 130
  • [22] Efficacy and safety results from a phase 1b/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma
    Hari, Parameswaran
    Paba-Prada, Claudia E.
    Voorhees, Peter M.
    Frye, John
    Chang, Yu-Lin
    Moreau, Philippe
    Zonder, Jeffrey
    Boccia, Ralph
    Shain, Kenneth H.
    [J]. LEUKEMIA RESEARCH, 2019, 83
  • [23] AN OPEN-LABEL, PHASE 1B STUDY (MMY1001) OF DARATUMUMAB COMBINED WITH CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (KRD) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (MM)
    Usmani, S. Z.
    Chari, A.
    Lonial, S.
    Weiss, B.
    Comenzo, R. L.
    Wu, K.
    Khokhar, N. Z.
    Wang, J.
    Doshi, P.
    Jakubowiak, A.
    [J]. HAEMATOLOGICA, 2017, 102 : 269 - 269
  • [24] A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
    Zonder, Jeffrey A.
    Mohrbacher, Ann F.
    Singhal, Seema
    van Rhee, Frits
    Bensinger, William I.
    Ding, Han
    Fry, John
    Afar, Daniel E. H.
    Singhal, Anil K.
    [J]. BLOOD, 2012, 120 (03) : 552 - 559
  • [25] MagnetisMM-5: An open-label, multicenter, randomized phase 3 study of elranatamab as monotherapy and in combination with daratumumab in patients with relapsed/refractory multiple myeloma.
    Grosicki, Sebastian
    Crafoord, Jacob
    Koh, Youngil
    White, Darrel
    Mellqvist, Ulf-Henrik
    Leip, Eric
    Kudla, Arthur
    Finn, Gregory
    Pruchniewski, Lukasz
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [26] A randomized phase II, open-label and multicenter study of combination regimens of bortezomib at two doses by subcutaneous injection for newly diagnosed multiple myeloma patients
    Li, Feng
    Yao, Fu-Sheng
    Zhu, Xi-Jun
    Gu, Wei-Ying
    Wang, Xiao-Hua
    Chen, Bing
    Huang, Dong-Ping
    Ding, Jia-Hua
    Wu, Tian-Qin
    Zhu, Yan
    Zhao, Qian
    Tang, Yu-Mei
    Song, Ping
    Zhou, Xiao-Gang
    An, Zhi-Ming
    Guo, Xing
    Wang, Xu-Li
    Zhong, Long
    Xie, Xiao-Bao
    Zhai, Yong-Ping
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2019, 145 (09) : 2343 - 2355
  • [27] A randomized phase II, open-label and multicenter study of combination regimens of bortezomib at two doses by subcutaneous injection for newly diagnosed multiple myeloma patients
    Feng Li
    Fu-Sheng Yao
    Xi-Jun Zhu
    Wei-Ying Gu
    Xiao-Hua Wang
    Bing Chen
    Dong-Ping Huang
    Jia-Hua Ding
    Tian-Qin Wu
    Yan Zhu
    Qian Zhao
    Yu-Mei Tang
    Ping Song
    Xiao-Gang Zhou
    Zhi-Ming An
    Xing Guo
    Xu-Li Wang
    Long Zhong
    Xiao-Bao Xie
    Yong-Ping Zhai
    [J]. Journal of Cancer Research and Clinical Oncology, 2019, 145 : 2343 - 2355
  • [28] Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study
    Chari, Ajai
    Rodriguez-Otero, Paula
    McCarthy, Helen
    Suzuki, Kenshi
    Hungria, Vania
    Balari, Anna Sureda
    Perrot, Aurore
    Hulin, Cyrille
    Magen, Hila
    Iida, Shinsuke
    Maisnar, Vladimir
    Karlin, Lionel
    Pour, Ludek
    Parasrampuria, Dolly A.
    Masterson, Tara
    Kosh, Michele
    Yang, Shiyi
    Delioukina, Maria
    Qi, Ming
    Carson, Robin
    Touzeau, Cyrille
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2021, 192 (05) : 869 - 878
  • [29] A Phase II, Open-Label Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma
    Stakiw, Julie
    Kodad, Shruthi
    LeBlanc, Richard
    Sebag, Michael
    Hay, Annette E.
    Kukreti, Vishal
    Cote, Julie
    Camacho, Fernando
    Fu, Molei
    Gul, Engin
    Reece, Donna
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (07): : 484 - 490
  • [30] Mavorixafor for Patients with Chronic Neutropenic Disorders: Results from a Phase 1b, Open-Label, Multicenter Study
    Warren, Julia T.
    Walkovich, Kelly J.
    Bolyard, Audrey Anna
    Dickerson, Kathryn E.
    Walter, Jolan E.
    Cadavid, Diego
    Chapa, Eloisa
    Chen, Kelly
    MacLeod, Richard
    Peters, Katie
    Polisson, Richard
    Dale, David C.
    [J]. BLOOD, 2022, 140 : 1408 - 1410
12345